Although HPV vaccines have been approved for young men, developers have yet to fully tap into the market. A new study has underlined the importance of the vaccine for men, and their partners as well.
Pennsylvania-based vaccine developer Inovio Pharmaceuticals has released positive Phase I results for its cervical dysplasia and cancer vaccine, VGX-3100. According to Dr. J. Joseph Kim, Inovio's
Roche gets FDA OK for HPV test
The FDA has given its blessing to Roche's cobas HPV test, which is designed to identify women at highest risk for developing cervical cancer. The test individually identifies HPV genotypes 16 and 18,
Cervical cancer vax ready to enter human trials
A low-cost cervical cancer vaccine developed by University of Colorado Cancer Center researchers is set to begin testing in human trials. Cervical cancer kills more than 350,000 women each year and
Inovio Pharmaceuticals says its DNA cervical cancer vaccine produced promising results in an early-stage study, with one dose group registering "unprecedented T-cell responses" for five out of six
Roughly two-thirds of young women eligible for receiving the HPV vaccine are aren't getting the shot--even though it can help guard against cervical cancer, according to a new report from researchers
GSK, Sanofi lobby Irish for HPV shots
Drugmakers are dispatching experts to the Emerald Isle to lobby for their human papillomavirus vaccines. That's because the Irish government has opted out of a comprehensive program to vaccinate
FDA grants Gardasil two new indications
Some good news for Merck's Gardasil: The FDA says the human papillomavirus vaccine is approved for prevention of vulvar and vaginal cancers, in addition to its current use as a cervical cancer shot.
Is Gardasil worth the cost?
Are HPV vaccines worth the cost? A study in the New England Journal of Medicine concludes that they aren't--at least not for women over 18. They'll only be cost-effective, the resesarchers decided,
Just how important Gardasil has become to Merck's top line is underscored by a New York Times article analyzing the impact of what the pharma company calls "educational programs" and just about